finance.yahoo.com / Yahoo! Finance
npub1vap…wc3n
2024-11-22 13:08:53
Author Public Key
npub1vap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aessgrwc3nSeen on
wss://articles.layer3.newsPublished at
2024-11-22 13:08:53Event JSON
{
"id": "0eae46f8cc2e514be961feee75783fbf1292fd3837c4c8a0477955992b2d6113",
"pubkey": "6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"created_at": 1732280933,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html"
],
[
"subject",
"BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell"
],
[
"published_at",
"1732275326"
],
[
"image",
"https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb"
],
[
"t",
"other:perspective"
],
[
"summary",
"BioLineRx and Ayrmid announced a license agreement for motixafortide, a stem cell mobilization agent, with BioLineRx granting Ayrmid an exclusive license to develop and commercialize Aphexda across all indications, excluding solid tumor indications. BioLineRx will receive a $10M upfront payment and potential commercial milestones. Ayrmid will add Aphexda to its commercial portfolio, which includes Omisirge, the first and only FDA-approved, nicotinamide-modified cell therapy."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nhttps://media.zenfs.com/en/tipranks_452/0176eac0ccabb4c894de3218c38cf5eb\n\nhttps://finance.yahoo.com/news/biolinerx-ayrmid-enter-license-agreement-113526432.html",
"sig": "b357e8dd486a6cac599a1bc30d9f8c33500b6210046079a3b127ec110c12a0cdc76f264464b130733f7f488d97110e9bd67e2ae8ec2fbd1df547ba339ce460db"
}